filmov
tv
BCMA: A new biomarker for multiple myeloma
Показать описание
Dr James Berenson talks to ecancer at the International Myeloma Workshop 2019 about BCMA or B-cell maturation antigen.
This is a novel marker for multiple myeloma which will improve the speed at which changes in clinical status can be determined, and is also a good prognostic marker.
The benefits of this marker therefore allow patients to move quickly away from a regimen that isn't working, or begin with less treatment.
Dr Berenson predicts that we could establish a threshold for the amount of BCMA in a patient which provides an accurate level of risk for developing myeloma.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
This is a novel marker for multiple myeloma which will improve the speed at which changes in clinical status can be determined, and is also a good prognostic marker.
The benefits of this marker therefore allow patients to move quickly away from a regimen that isn't working, or begin with less treatment.
Dr Berenson predicts that we could establish a threshold for the amount of BCMA in a patient which provides an accurate level of risk for developing myeloma.
Sign up to ecancer for free to receive tailored email alerts for more videos like this.
0:03:10
0:17:20
0:05:12
0:01:43
0:04:21
0:05:06
0:01:54
0:05:59
0:02:36
0:02:23
0:01:56
0:20:03
0:09:56
0:04:29
0:05:00
0:01:58
0:02:33
0:17:24
0:31:00
0:05:26
0:17:05
0:04:41
0:03:05
0:00:53